Ras association domain family member 2Genealiases: CENP-34 · RASFADIN
Q-omics provides the consensus-scored RASSF2 profile across patient tissues and cancer cell-line models. RASSF2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RASSF2 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, RASSF2 protein abundance shows 27,243 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where RASSF2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RASSF2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RASSF2 survival associations across molecular data types. RASSF2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RASSF2 RNA expression–survival associations across cancer types. High RASSF2 expression shows unfavorable associations in MESO and UVM, but favorable associations in HNSC, LUAD, KIRC and SARC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for RASSF2 RNA expression.
This table summarizes RASSF2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RASSF2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RASSF2 shows lower tumor expression in LUAD, COAD, LUSC and UCEC and higher tumor expression in KIRC and KIRP. The KIRC box plot shows higher RASSF2 RNA expression in tumor versus normal tissue (log2 FC = +2.375, t-test p < 0.001).
This table shows molecular features associated with RASSF2 in patient tissues and cancer cell lines. In patient samples, RASSF2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RASSF2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
